CHPF Knockout Raji Polyclonal Cells are a polyclonal population of CRISPR/Cas9-edited Raji B lymphocytes with targeted disruption of the CHPF gene. These polyclonal knockout cells offer a mixed genetic background reflecting a spectrum of gene-editing events, providing a robust loss-of-function model free from clonal artifacts. Suitable for expansion and multiple downstream assays, they serve as a versatile tool for studying CHPF-dependent biology.
The parental Raji cell line is an EBV-positive Burkitt’s lymphoma-derived B lymphoblastoid line that retains critical B-cell characteristics, including surface immunoglobulin expression and antigen-presenting capacity. Raji cells are widely employed as a model system for B-lymphocyte biology, EBV latency, and oncogenic transformation, making them a relevant host for examining the role of glycosaminoglycan modifications in lymphoid malignancies.
CHPF (chondroitin polymerizing factor) catalyzes the polymerization of the chondroitin sulfate backbone, a repeating disaccharide unit of glucuronic acid and N-acetylgalactosamine, onto proteoglycan core proteins. This step is coordinated with chondroitin synthase enzymes (CHSY1, CHSY3) and initiation factors (CSGALNACT1/2). Upstream, transcription factors such as SOX9 and signaling pathways including TGF-?? and BMP regulate CHPF expression, linking it to developmental and pathological cues. Downstream, CHPF-dependent CS chains decorate proteoglycans like aggrecan, versican, CD44, and syndecans, which modulate cell adhesion, growth factor presentation, and extracellular matrix organization.
In the Raji B-cell context, CHPF-mediated CS synthesis influences the composition of the glycocalyx, which governs cell-cell and cell-matrix interactions. Disruption of CHPF in these lymphoma cells alters surface proteoglycan structures, potentially affecting adhesion, migration, and signaling events critical for immune-cell function and tumor behavior. This polyclonal knockout model thus enables the study of how aberrant glycosylation contributes to B-cell malignancies, EBV-associated pathology, and the remodeling of the tumor microenvironment.
Research applications for CHPF Knockout Raji Polyclonal Cells encompass biochemical validation via Western blot or RT-qPCR, glycosaminoglycan profiling by HPLC or mass spectrometry, and flow cytometry with anti-chondroitin sulfate antibodies. Functional assays such as cell adhesion, migration, and invasion studies can dissect the role of CS in B-cell trafficking. Additionally, this model supports drug discovery efforts targeting the glycosaminoglycan pathway in cancer. For further details, please contact Ascent Research.
